Trials / Completed
CompletedNCT00634621
Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer
A Post-authorization, Observational Study to Assess the Impact of Blue Light Cystoscopy After Administration of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 283 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of hexaminolevulinate (Hexvix) in the diagnosis and treatment of patients with non-invasive bladder cancer and if it results in a change in patient management.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hexaminolevulinate (Hexvix) | Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied. |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2008-03-13
- Last updated
- 2014-08-25
- Results posted
- 2014-08-25
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00634621. Inclusion in this directory is not an endorsement.